ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis

Autor(es)

Zheng, Q. ^[1] ; Wu, H. ^[2] ; Yu, Q. ^[3] ; Kim, D. H. (Dennis) ^[4] ; Lipton, J. H. ^[4] ; Angelini, S. ^[5] ; Soverini, S. ^[6] ; Vivona, D. ^[7] ; Takahashi, N. ^[8] ; Cao, J. ^[1]

Afiliação do(s) autor(es)

^[1] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Clin Res Ctr, Hangzhou 310009, Zhejiang - Peoples R China

^[2] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Neurosurg, Hangzhou 310003, Zhejiang - Peoples R China

^[3] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Surg Oncol, Hangzhou 310003, Zhejiang - Peoples R China

^[4] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Chron Myelogenous Leukemia Grp, Toronto, ON - Canada

^[5] Univ Bologna, Dept Pharm & Biotechnol, Bologna - Italy

^[6] Univ Bologna, Inst Hematol, Dept Expt Diagnost & Specialty Med, Bologna - Italy

^[7] Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Anal Clin & Toxicol, Sao Paulo - Brazil

^[8] Akita Univ, Grad Sch Med, Dept Hematol Nephrol & Rheumatol, Akita 010 - Japan

• Tipo de documento: Artigo Científico
• Fonte: PHARMACOGENOMICS JOURNAL; v. 15, n. 2, p. 127-134, APR 2015.
• Citações Web of Science: 26

Resumo

Imatinib mesylate, a competitive tyrosine kinase inhibitor, is considered the first-line therapy drug for Ph+ chronic myeloid leukemia (CML). Three single-nucleotide polymorphisms (SNPs) in the ATP-binding cassette, subfamily B (MDR/TAP), member 1 gene (ABCB1/MDR1), c.1236C>T, c.2677G>T/A and c.3435C>T, have been shown to affect cellular transport/metabolism of imatinib. The associations between these SNPs and imatinib response in CML patients have been widely evaluated, but the results were inconsistent. To derive a conclusive assessment of the associations, we performed a meta-analysis by combining data from a total of 12 reports including 1826 patients. The results showed that the 2677G allele or 3435T allele predicted a worse response to imatinib in CML patients, whereas 1236CC genotype was associated with better response in CML patients from Asian region. In conclusion, this meta-analysis suggests that c.1236C>T, c.2677G>T/A and c.3435C>T can be served as predictive markers for the therapeutical use of imatinib in CML patients. (AU)

• Processo FAPESP: 09/54184-0 - Estudo da expressao de transportadores de membrana e sua relacao com marcadores de resposta ao mesilato de imatinibe em pacientes com leucemia mieloide cronica.
• Beneficiário: Elvira Maria Guerra Shinohara
• Modalidade de apoio: Auxílio à Pesquisa - Regular